SEC16A and colorectal cancer: found that the IgM autoantibodies against CADM1, ICLN, SEC16, and ZNF768 were increased in the serum of colorectal cancer patients and demonstrated that these IgM autoantibodies are potential biomarkers for colorectal cancer (25).